Reviewer’s report

Title: A new mouse model to study the role of ectopic Nanos3 expression in cancer

Version: 0 Date: 07 Dec 2018

Reviewer: Yihua Wang

Reviewer’s report:

In this manuscript (BCAN-D-18-02739), the authors reported a new mouse model allowing examination of Nanos3-associated pathways and investigation of the influence of ectopic Nanos3 expression in various cancer types, particularly in lung cancer. Although without the insight of mechanism, this study provided in vivo evidence regarding the role of Nanos3 in the progression of lung cancer.

Several points need to be addressed before publication.

1). Since this mouse model is an inducible ectopic overexpression, is the level comparable to that in human lung cancer? I understand it is difficult to compare, but some western blots with those lung tumor-derived cells and established human lung cancer cell lines may help.

2) Please include some zoom-in pictures for IHC and H/E images.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

n/a

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal